Cortagen vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & LongevityRecovery & Repair
CortagenGLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide- Summary
- Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- SubQ, IM, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg SC or IM daily
- 5 mcg, titrate to 10 mcg
- Frequency
- Once daily
- Twice daily
- Key Benefits
- Cardioprotective — protects cardiac tissue from ischemic damage
- Promotes cardiac regeneration and repair
- Improves vascular endothelium function
- Reduces atherosclerosis progression
- Anti-aging effect on heart muscle cells
- Improves cardiac output and exercise capacity
- Reduces oxidative stress in cardiovascular tissue
- May reduce arrhythmia frequency
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Excellent safety profile
- Mild injection site reactions
- Rare: transient hypotension
- Rare: mild arrhythmia at initiation in cardiac patients
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —